---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-012517"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:31:55.869393+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q2 net loss $40.5M, down from $78.5M YoY; cash $231.8M

## Summary
- Net loss of $40.5M in Q2 2022 vs $78.5M in Q2 2021; six-month loss $109.5M vs $169.1M.
- R&D expenses $26.9M (Q2 2022) vs $44.9M (Q2 2021), down on cost-saving measures and UKONIQ withdrawal.
- Cash & investments $231.8M at June 30, 2022; expected to fund operations into H2 2023.
- PDUFA goal date for ublituximab in RMS set for December 28, 2022; preparing for potential early 2023 launch.

## SEC filing metadata
- accession: 0001558370-22-012517
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/0001558370-22-012517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/tgtx-20220808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-012517
- JSON: https://secwatch.observer/filing/0001558370-22-012517.json
- Plain text: https://secwatch.observer/filing/0001558370-22-012517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.